NK-1R antagonists are known to prevent tumor cell proliferation, invasion, and metastasis via suppression of the Wnt/β-catenin signaling pathway, and it has been suggested that, before and after cancer surgical procedures, Aprepitant could be administered to prevent metastasis and recurrence [132,133]. The gene discussed is TACR1; the disease is neoplasm.